از ویکی‌پدیا، دانشنامهٔ آزاد
مزوتلین (انگلیسی : Mesothelin پروتئین است که در انسان توسط ژن «MSLN » کُدگذاری می‌شود.[ ۴] [ ۵] مزوتلیال بیان می‌شود[ ۶] [ ۷]
امروزه مشخص شده است که این پروتئین در چندین تومور انسانی بیش از حد ساخته می شودِ از جمله مزوتلیوما ، سرطان تخمدان ، آدنوکارسینوم لوزالمعده[ ۶] سرطان لوزالمعده )، آدنوکارسینوم ریه[ ۸] کلانژیوکارسینوما [ ۹] مزوتلیال پوشاننده پرده جنب ،[ ۱۰] صفاق و پریکارد وجود دارد.[ ۶] بیان می‌شود و ایمونوژنیک است، این پروتئین را می‌توان به عنوان نشانگر تومور یا به عنوان هدف آنتی‌ژنی برای واکسن‌درمانی سرطان مورد استفاده قرار داد.[ ۱۱] [ ۱۲]
↑ ۱٫۰ ۱٫۱ ۱٫۲ GRCm38: Ensembl release 89: ENSMUSG00000063011 - Ensembl , May 2017↑ "Human PubMed Reference:" . National Center for Biotechnology Information, U.S. National Library of Medicine .↑ "Mouse PubMed Reference:" . National Center for Biotechnology Information, U.S. National Library of Medicine .↑ Kojima T, Oh-eda M, Hattori K, Taniguchi Y, Tamura M, Ochi N, Yamaguchi N (September 1995). "Molecular cloning and expression of megakaryocyte potentiating factor cDNA" . The Journal of Biological Chemistry . 270 (37): 21984–21990. doi :10.1074/jbc.270.37.21984 PMID 7665620 . ↑ Chang K, Pastan I (January 1996). "Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers" . Proceedings of the National Academy of Sciences of the United States of America . 93 (1): 136–140. Bibcode :1996PNAS...93..136C . doi :10.1073/pnas.93.1.136 PMC 40193 PMID 8552591 . ↑ ۶٫۰ ۶٫۱ ۶٫۲ Hassan R, Ho M (January 2008). "Mesothelin targeted cancer immunotherapy" . European Journal of Cancer . 44 (1): 46–53. doi :10.1016/j.ejca.2007.08.028 . PMC 2265108 PMID 17945478 . ↑ Chang K, Pai LH, Batra JK, Pastan I, Willingham MC (January 1992). "Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium" . Cancer Research . 52 (1): 181–186. PMID 1727378 . ↑ Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I (March 2007). "Mesothelin expression in human lung cancer" . Clinical Cancer Research . 13 (5): 1571–1575. doi :10.1158/1078-0432.CCR-06-2161 PMID 17332303 . ↑ Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, et al. (October 2010). "Mesothelin as a potential therapeutic target in human cholangiocarcinoma" . Journal of Cancer . 1 : 141–149. doi :10.7150/jca.1.141 . PMC 2948219 PMID 20922056 . ↑ Grosso F, Mannucci M, Ugo F, Ferro P, Cassinari M, Vigani A, et al. (October 2021). "Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score" . Diagnostics . 11 (11): 2015. doi :10.3390/diagnostics11112015 PMC 8623660 PMID 34829362 . ↑ Hassan R, Bera T, Pastan I (June 2004). "Mesothelin: a new target for immunotherapy" . Clinical Cancer Research . 10 (12 Pt 1): 3937–3942. doi :10.1158/1078-0432.CCR-03-0801 PMID 15217923 . ↑ Hassan R, Ho M (January 2008). "Mesothelin targeted cancer immunotherapy" . European Journal of Cancer . 44 (1): 46–53. doi :10.1016/j.ejca.2007.08.028 . PMC 2265108 PMID 17945478 .
Alvarez H, Rojas PL, Yong KT, Ding H, Xu G, Prasad PN, et al. (December 2008). "Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy" . Nanomedicine . 4 (4): 295–301. doi :10.1016/j.nano.2008.06.006 . PMC 2606904 PMID 18691948 . Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, et al. (April 2010). "Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein". Occupational and Environmental Medicine . 67 (4): 233–236. doi :10.1136/oem.2009.049205 . PMID 19858537 . S2CID 207017988 . Pu RT, Pang Y, Michael CW (January 2008). "Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions" . Diagnostic Cytopathology . 36 (1): 20–25. doi :10.1002/dc.20747 hdl :2027.42/57547 PMID 18064689 . S2CID 10096707 . Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, et al. (December 2008). "Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma" . Oncology Reports . 20 (6): 1375–1380. doi :10.3892/or_00000155 PMID 19020717 . Johnson MD, Vito F, O'Connell MJ (June 2008). "Mesothelin expression in the leptomeninges and meningiomas" . The Journal of Histochemistry and Cytochemistry . 56 (6): 579–585. doi :10.1369/jhc.2008.950477 . PMC 2386771 PMID 18347077 . Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T (November 2008). "Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer" . Journal of Thoracic Oncology . 3 (11): 1317–1324. doi :10.1097/JTO.0b013e318187491c PMID 18978568 . S2CID 5183602 . Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, et al. (January 2008). "Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions" . The Annals of Thoracic Surgery . 85 (1): 265–72, discussion 272. doi :10.1016/j.athoracsur.2007.07.042 PMID 18154821 . Sapede C, Gauvrit A, Barbieux I, Padieu M, Cellerin L, Sagan C, et al. (March 2008). "Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells" . Cancer Science . 99 (3): 590–594. doi :10.1111/j.1349-7006.2007.00715.x PMID 18167128 . S2CID 205233632 . Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, et al. (February 2008). "Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer" . Molecular Cancer Therapeutics . 7 (2): 286–296. doi :10.1158/1535-7163.MCT-07-0483 . PMC 2929838 PMID 18281514 . Uehara N, Matsuoka Y, Tsubura A (February 2008). "Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells" . Molecular Cancer Research . 6 (2): 186–193. doi :10.1158/1541-7786.MCR-07-0254 PMID 18245228 . Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, et al. (October 2008). "Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin". Lung Cancer . 62 (1): 45–54. doi :10.1016/j.lungcan.2008.02.012 . PMID 18394747 . Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW (August 2008). "Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma" . Journal of Thoracic Oncology . 3 (8): 851–857. doi :10.1097/JTO.0b013e318180477b PMID 18670302 . S2CID 12405738 . Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, et al. (March 2008). "Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma" . Clinical Cancer Research . 14 (5): 1431–1437. doi :10.1158/1078-0432.CCR-07-1613 PMID 18316566 . Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M (February 2009). "A binding domain on mesothelin for CA125/MUC16" . The Journal of Biological Chemistry . 284 (6): 3739–3749. doi :10.1074/jbc.M806776200 PMC 2635045 PMID 19075018 . Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH, Cheng WF (December 2009). "Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway". The Biochemical Journal . 424 (3): 449–458. doi :10.1042/BJ20082196 . PMID 19747165 . Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL, et al. (April 2009). "High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma" . British Journal of Cancer . 100 (7): 1144–1153. doi :10.1038/sj.bjc.6604964 . PMC 2669998 PMID 19293794 . Hellstrom I, Hellstrom KE (2008). "SMRP and HE4 as Biomarkers for Ovarian Carcinoma when Used Alone and in Combination with CA125 and/Or Each Other" . Ovarian Cancer . Advances in Experimental Medicine and Biology. Vol. 622. pp. 15–21 . doi :10.1007/978-0-387-68969-2_2 . ISBN 978-0-387-68966-1 PMID 18546615 . Bharadwaj U, Li M, Chen C, Yao Q (November 2008). "Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3" . Molecular Cancer Research . 6 (11): 1755–1765. doi :10.1158/1541-7786.MCR-08-0095 . PMC 2929833 PMID 19010822 .
